Home
Live Updates
Liminal BioSciences Inc.: Liminal BioSciences Provides R&D Update : comparemela.com
Liminal BioSciences Inc.: Liminal BioSciences Provides R&D Update
LMNL6326 nominated as lead preclinical candidate for OXER1 antagonist development program, targeting the treatment of eosinophil-driven diseasesAdvancement of clinical trial application (CTA)
Related Keywords
United Kingdom ,
Cambridge ,
Cambridgeshire ,
Canada ,
Fairhaven ,
Newfoundland ,
Canadian ,
Shrinal Inamdar ,
Bruce Pritchard ,
Kaitlin Gallagher ,
Exchange Commission ,
World Health Organisation ,
Market Watch Research ,
Securities Exchange ,
Fairhaven Pharmaceuticals Inc ,
Liminal Biosciences Inc ,
Agonist Development Program ,
Antagonist Development Program ,
Prnewswire Liminal Biosciences Inc ,
Nasdaq ,
Chief Executive Officer ,
Watch Research ,
Future Market Insights ,
Gary Bridger ,
Interim Chief Scientific Officer ,
Study Results ,
About Liminal Biosciences ,
Securities Act ,
Securities Exchange Act ,
Liminal Bioscience ,
Nasdaq Listing Rule ,
Nasdaq Capital Market ,
Canadian Securities Administrators ,
Annual Report ,
Associate Director ,
Investor Relations ,
Media Contact ,
Liminal ,
Iosciences ,
Rovides ,
Update ,
comparemela.com © 2020. All Rights Reserved.